Share Price and Basic Stock Data
Last Updated: December 29, 2025, 11:16 pm
| PEG Ratio | 1.95 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Everest Organics Ltd operates in the pharmaceuticals sector, with its stock currently priced at ₹502 and a market capitalization of ₹488 Cr. The company reported sales of ₹183 Cr for the fiscal year ending March 2023, reflecting a decline from ₹200 Cr in the previous fiscal year. The trailing twelve months (TTM) sales figure stood at ₹188 Cr, indicating a slight recovery in sales performance. Quarterly sales trends revealed variability, with the highest quarterly sales of ₹52.62 Cr recorded in March 2024, followed by a drop to ₹32.45 Cr in June 2024. The company’s operating profit margin (OPM) showed fluctuations, reaching 10.06% in September 2025, showcasing some operational resilience despite the earlier volatility in revenue. Overall, the revenue trajectory exhibits a pattern of inconsistency, which may concern investors regarding the company’s ability to maintain stable growth in a competitive pharmaceutical market.
Profitability and Efficiency Metrics
Profitability metrics for Everest Organics Ltd reveal challenges, with a reported net profit of ₹7 Cr for the latest fiscal year, translating to a low return on equity (ROE) of 2.23% and a return on capital employed (ROCE) of 1.76%. The operating profit for the fiscal year ending March 2025 is projected to be ₹7 Cr, down from ₹11 Cr in March 2024, indicating potential operational inefficiencies. The interest coverage ratio (ICR) stood at 1.52x, suggesting limited capacity to meet interest obligations, which may pose financial risks. The company also reported a cash conversion cycle (CCC) of 17 days, indicating a relatively efficient management of working capital. However, the inconsistent profitability and low margins, particularly with a net profit margin of -0.80% for the year ending March 2025, highlight the need for strategic measures to enhance operational efficiency and profitability.
Balance Sheet Strength and Financial Ratios
The balance sheet of Everest Organics Ltd indicates moderate financial health, with total borrowings reported at ₹49 Cr against reserves of ₹63 Cr. The company’s total liabilities stood at ₹224 Cr, with total assets at ₹224 Cr, reflecting a balanced equation. The debt-to-equity ratio of 0.68x suggests a manageable level of leverage, although it is higher than ideal for conservative investors. The book value per share, reported at ₹72.03, shows an increase from ₹57.30 in the previous fiscal year, which may indicate improved shareholder equity positioning. The current ratio of 1.06x signifies liquidity adequacy, although it is slightly above the typical sector threshold. Overall, while the company maintains a balanced financial structure, the reliance on debt and declining profitability metrics may warrant caution for potential investors.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Everest Organics Ltd reveals a significant promoter holding of 59.64%, down from 74.15% in December 2022, which may raise concerns regarding insider confidence in the firm. The public shareholding has increased to 40.35%, indicating growing investor interest, albeit with foreign institutional investors (FIIs) showing no participation and domestic institutional investors (DIIs) holding a mere 0.02%. The number of shareholders has also decreased to 8,079, reflecting potential consolidation among retail investors. The lack of substantial institutional backing could impact the stock’s liquidity and overall market perception, especially in uncertain economic conditions. Despite these concerns, the increase in public shareholding may signal a shift towards greater retail investor confidence, suggesting a potential for future growth if operational challenges are addressed effectively.
Outlook, Risks, and Final Insight
Looking ahead, Everest Organics Ltd faces both opportunities and challenges. The company’s ability to stabilize revenue and improve profitability will be critical, especially given the current low ROE and ROCE figures. Key risks include its reliance on debt and the declining trend in net profits, which could limit financial flexibility. However, strengths such as a manageable debt level and a solid shareholder base could provide a foundation for recovery. Should the company successfully enhance its operational efficiencies and manage costs, it may regain investor confidence and improve its financial metrics. Conversely, failure to address these operational issues could lead to further declines in profitability and market valuation. Thus, while there are pathways for potential recovery, vigilance and strategic initiatives will be essential for mitigating risks and capitalizing on market opportunities.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 122 Cr. | 97.0 | 231/84.3 | 27.0 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.54 Cr. | 1.85 | 4.29/1.76 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,881 Cr. | 448 | 479/192 | 101 | 24.3 | 0.15 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 32.9 Cr. | 44.3 | 88.6/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 50.8 Cr. | 34.7 | 35.0/17.0 | 121 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 20,009.32 Cr | 1,139.65 | 52.68 | 202.18 | 0.36% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 45.97 | 43.29 | 50.75 | 42.67 | 49.45 | 52.51 | 52.62 | 32.45 | 44.05 | 42.05 | 40.93 | 53.81 | 51.00 |
| Expenses | 43.20 | 45.79 | 48.47 | 40.15 | 46.74 | 49.71 | 49.67 | 36.11 | 40.62 | 38.03 | 37.49 | 49.37 | 45.87 |
| Operating Profit | 2.77 | -2.50 | 2.28 | 2.52 | 2.71 | 2.80 | 2.95 | -3.66 | 3.43 | 4.02 | 3.44 | 4.44 | 5.13 |
| OPM % | 6.03% | -5.78% | 4.49% | 5.91% | 5.48% | 5.33% | 5.61% | -11.28% | 7.79% | 9.56% | 8.40% | 8.25% | 10.06% |
| Other Income | 0.22 | 5.65 | 0.69 | 0.22 | 0.24 | 0.13 | 0.30 | 0.33 | 0.14 | 0.00 | 0.22 | 0.55 | 0.29 |
| Interest | 0.85 | 0.81 | 0.95 | 1.29 | 1.49 | 1.45 | 1.24 | 1.29 | 1.35 | 1.40 | 1.15 | 1.31 | 1.23 |
| Depreciation | 1.13 | 1.10 | 1.26 | 1.29 | 1.32 | 1.33 | 1.85 | 1.47 | 1.47 | 1.47 | 1.56 | 1.52 | 1.52 |
| Profit before tax | 1.01 | 1.24 | 0.76 | 0.16 | 0.14 | 0.15 | 0.16 | -6.09 | 0.75 | 1.15 | 0.95 | 2.16 | 2.67 |
| Tax % | 6.93% | -21.77% | 85.53% | 75.00% | 78.57% | 93.33% | 62.50% | 0.00% | 1.33% | 0.87% | -206.32% | 35.19% | 56.93% |
| Net Profit | 0.94 | 1.52 | 0.11 | 0.04 | 0.03 | 0.02 | 0.06 | -6.09 | 0.74 | 1.14 | 2.91 | 1.41 | 1.16 |
| EPS in Rs | 1.18 | 1.90 | 0.14 | 0.05 | 0.04 | 0.02 | 0.08 | -7.61 | 0.92 | 1.42 | 3.00 | 1.45 | 1.19 |
Last Updated: December 27, 2025, 1:04 am
Below is a detailed analysis of the quarterly data for Everest Organics Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Sales, as of Sep 2025, the value is 51.00 Cr.. The value appears to be declining and may need further review. It has decreased from 53.81 Cr. (Jun 2025) to 51.00 Cr., marking a decrease of 2.81 Cr..
- For Expenses, as of Sep 2025, the value is 45.87 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 49.37 Cr. (Jun 2025) to 45.87 Cr., marking a decrease of 3.50 Cr..
- For Operating Profit, as of Sep 2025, the value is 5.13 Cr.. The value appears strong and on an upward trend. It has increased from 4.44 Cr. (Jun 2025) to 5.13 Cr., marking an increase of 0.69 Cr..
- For OPM %, as of Sep 2025, the value is 10.06%. The value appears strong and on an upward trend. It has increased from 8.25% (Jun 2025) to 10.06%, marking an increase of 1.81%.
- For Other Income, as of Sep 2025, the value is 0.29 Cr.. The value appears to be declining and may need further review. It has decreased from 0.55 Cr. (Jun 2025) to 0.29 Cr., marking a decrease of 0.26 Cr..
- For Interest, as of Sep 2025, the value is 1.23 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 1.31 Cr. (Jun 2025) to 1.23 Cr., marking a decrease of 0.08 Cr..
- For Depreciation, as of Sep 2025, the value is 1.52 Cr.. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 1.52 Cr..
- For Profit before tax, as of Sep 2025, the value is 2.67 Cr.. The value appears strong and on an upward trend. It has increased from 2.16 Cr. (Jun 2025) to 2.67 Cr., marking an increase of 0.51 Cr..
- For Tax %, as of Sep 2025, the value is 56.93%. The value appears to be increasing, which may not be favorable. It has increased from 35.19% (Jun 2025) to 56.93%, marking an increase of 21.74%.
- For Net Profit, as of Sep 2025, the value is 1.16 Cr.. The value appears to be declining and may need further review. It has decreased from 1.41 Cr. (Jun 2025) to 1.16 Cr., marking a decrease of 0.25 Cr..
- For EPS in Rs, as of Sep 2025, the value is 1.19. The value appears to be declining and may need further review. It has decreased from 1.45 (Jun 2025) to 1.19, marking a decrease of 0.26.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 3:45 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 96 | 106 | 99 | 107 | 112 | 156 | 167 | 182 | 200 | 183 | 197 | 159 | 188 |
| Expenses | 91 | 98 | 94 | 101 | 105 | 138 | 148 | 159 | 194 | 182 | 186 | 152 | 171 |
| Operating Profit | 5 | 8 | 6 | 6 | 7 | 18 | 19 | 23 | 6 | 1 | 11 | 7 | 17 |
| OPM % | 6% | 7% | 6% | 6% | 6% | 11% | 12% | 13% | 3% | 1% | 6% | 5% | 9% |
| Other Income | 1 | -0 | -0 | 1 | 1 | 1 | 1 | 1 | 2 | 7 | 1 | 1 | 1 |
| Interest | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 5 | 5 | 5 |
| Depreciation | 2 | 3 | 3 | 2 | 3 | 3 | 3 | 3 | 4 | 4 | 6 | 6 | 6 |
| Profit before tax | 1 | 2 | 0 | 2 | 2 | 12 | 14 | 17 | 2 | 0 | 1 | -3 | 7 |
| Tax % | 21% | 20% | 18% | 24% | 28% | 39% | 23% | 21% | 34% | 311% | 77% | -60% | |
| Net Profit | 1 | 2 | 0 | 1 | 2 | 8 | 11 | 14 | 1 | -0 | 0 | -1 | 7 |
| EPS in Rs | 0.54 | 1.69 | 2.14 | 9.39 | 13.62 | 17.15 | 1.42 | -0.22 | 0.18 | -1.33 | 7.06 | ||
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 11% | 7% | 9% | 0% | 0% | 0% | 0% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 |
|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 100.00% | -100.00% | 100.00% | 300.00% | 37.50% | 27.27% | -92.86% | -100.00% |
| Change in YoY Net Profit Growth (%) | 0.00% | -200.00% | 200.00% | 200.00% | -262.50% | -10.23% | -120.13% | -7.14% |
Everest Organics Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 8 years from 2014-2015 to 2022-2023.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 4% |
| 5 Years: | -1% |
| 3 Years: | -7% |
| TTM: | -3% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 204% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | 7% |
| 3 Years: | 44% |
| 1 Year: | 182% |
| Return on Equity | |
|---|---|
| 10 Years: | 11% |
| 5 Years: | 6% |
| 3 Years: | -1% |
| Last Year: | -2% |
Last Updated: September 5, 2025, 3:26 pm
Balance Sheet
Last Updated: December 10, 2025, 4:17 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 9 | 9 | 3 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 10 | 10 |
| Reserves | -5 | -3 | 3 | 8 | 11 | 18 | 26 | 39 | 39 | 38 | 38 | 60 | 63 |
| Borrowings | 26 | 24 | 28 | 19 | 22 | 21 | 18 | 23 | 39 | 51 | 58 | 48 | 49 |
| Other Liabilities | 35 | 37 | 42 | 51 | 54 | 60 | 68 | 66 | 92 | 105 | 123 | 107 | 115 |
| Total Liabilities | 65 | 67 | 76 | 86 | 94 | 107 | 120 | 135 | 178 | 202 | 227 | 224 | 237 |
| Fixed Assets | 24 | 24 | 27 | 33 | 34 | 38 | 39 | 44 | 49 | 54 | 54 | 50 | 49 |
| CWIP | 0 | 0 | 1 | 1 | 1 | 0 | 1 | 0 | 8 | 12 | 19 | 23 | 22 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 41 | 42 | 47 | 52 | 60 | 68 | 80 | 92 | 121 | 136 | 153 | 152 | 166 |
| Total Assets | 65 | 67 | 76 | 86 | 94 | 107 | 120 | 135 | 178 | 202 | 227 | 224 | 237 |
Below is a detailed analysis of the balance sheet data for Everest Organics Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 10.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 10.00 Cr..
- For Reserves, as of Sep 2025, the value is 63.00 Cr.. The value appears strong and on an upward trend. It has increased from 60.00 Cr. (Mar 2025) to 63.00 Cr., marking an increase of 3.00 Cr..
- For Borrowings, as of Sep 2025, the value is 49.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 48.00 Cr. (Mar 2025) to 49.00 Cr., marking an increase of 1.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 115.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 107.00 Cr. (Mar 2025) to 115.00 Cr., marking an increase of 8.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 237.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 224.00 Cr. (Mar 2025) to 237.00 Cr., marking an increase of 13.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 49.00 Cr.. The value appears to be declining and may need further review. It has decreased from 50.00 Cr. (Mar 2025) to 49.00 Cr., marking a decrease of 1.00 Cr..
- For CWIP, as of Sep 2025, the value is 22.00 Cr.. The value appears to be declining and may need further review. It has decreased from 23.00 Cr. (Mar 2025) to 22.00 Cr., marking a decrease of 1.00 Cr..
- For Investments, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Other Assets, as of Sep 2025, the value is 166.00 Cr.. The value appears strong and on an upward trend. It has increased from 152.00 Cr. (Mar 2025) to 166.00 Cr., marking an increase of 14.00 Cr..
- For Total Assets, as of Sep 2025, the value is 237.00 Cr.. The value appears strong and on an upward trend. It has increased from 224.00 Cr. (Mar 2025) to 237.00 Cr., marking an increase of 13.00 Cr..
Notably, the Reserves (63.00 Cr.) exceed the Borrowings (49.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -21.00 | -16.00 | -22.00 | -13.00 | -15.00 | -3.00 | 1.00 | 0.00 | -33.00 | -50.00 | -47.00 | -41.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 106 | 100 | 117 | 105 | 124 | 95 | 97 | 102 | 125 | 152 | 185 | 202 |
| Inventory Days | 46 | 44 | 55 | 73 | 72 | 71 | 102 | 110 | 110 | 139 | 128 | 166 |
| Days Payable | 184 | 184 | 235 | 260 | 251 | 190 | 211 | 183 | 212 | 282 | 324 | 351 |
| Cash Conversion Cycle | -32 | -40 | -63 | -83 | -55 | -24 | -12 | 29 | 24 | 9 | -11 | 17 |
| Working Capital Days | -43 | -30 | -38 | -50 | -34 | -15 | 7 | 21 | 9 | -12 | -21 | 3 |
| ROCE % | 13% | 19% | 11% | 13% | 13% | 35% | 35% | 34% | 6% | 4% | 6% | 2% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | -2.97 | 0.17 | -0.23 | 1.43 | 17.14 |
| Diluted EPS (Rs.) | -2.97 | 0.17 | -0.23 | 1.43 | 17.14 |
| Cash EPS (Rs.) | 4.81 | 7.42 | 5.36 | 6.17 | 21.36 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 72.03 | 57.30 | 57.77 | 58.50 | 58.22 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 72.03 | 57.30 | 57.77 | 58.50 | 58.22 |
| Dividend / Share (Rs.) | 0.00 | 0.00 | 0.00 | 0.50 | 1.50 |
| Revenue From Operations / Share (Rs.) | 164.23 | 246.55 | 228.81 | 250.06 | 226.96 |
| PBDIT / Share (Rs.) | 8.14 | 14.84 | 9.84 | 10.80 | 29.88 |
| PBIT / Share (Rs.) | 2.00 | 7.60 | 4.25 | 6.05 | 25.66 |
| PBT / Share (Rs.) | -3.34 | 0.76 | 0.11 | 2.17 | 21.59 |
| Net Profit / Share (Rs.) | -1.33 | 0.17 | -0.22 | 1.43 | 17.14 |
| PBDIT Margin (%) | 4.95 | 6.01 | 4.30 | 4.31 | 13.16 |
| PBIT Margin (%) | 1.22 | 3.08 | 1.85 | 2.42 | 11.30 |
| PBT Margin (%) | -2.03 | 0.30 | 0.04 | 0.86 | 9.51 |
| Net Profit Margin (%) | -0.80 | 0.07 | -0.09 | 0.57 | 7.55 |
| Return on Networth / Equity (%) | -1.84 | 0.30 | -0.39 | 2.44 | 29.44 |
| Return on Capital Employeed (%) | 2.30 | 9.12 | 5.28 | 7.39 | 35.38 |
| Return On Assets (%) | -0.57 | 0.06 | -0.09 | 0.64 | 10.13 |
| Long Term Debt / Equity (X) | 0.13 | 0.31 | 0.25 | 0.23 | 0.12 |
| Total Debt / Equity (X) | 0.68 | 1.26 | 1.10 | 0.82 | 0.42 |
| Asset Turnover Ratio (%) | 0.70 | 0.92 | 0.96 | 1.28 | 1.42 |
| Current Ratio (X) | 1.06 | 0.93 | 0.96 | 1.05 | 1.15 |
| Quick Ratio (X) | 0.73 | 0.66 | 0.62 | 0.67 | 0.72 |
| Inventory Turnover Ratio (X) | 3.58 | 2.73 | 2.83 | 3.77 | 3.85 |
| Dividend Payout Ratio (NP) (%) | 0.00 | 0.00 | -219.53 | 69.94 | 8.74 |
| Dividend Payout Ratio (CP) (%) | 0.00 | 0.00 | 9.32 | 16.19 | 7.02 |
| Earning Retention Ratio (%) | 0.00 | 0.00 | 319.53 | 30.06 | 91.26 |
| Cash Earning Retention Ratio (%) | 0.00 | 0.00 | 90.68 | 83.81 | 92.98 |
| Interest Coverage Ratio (X) | 1.52 | 2.17 | 2.38 | 2.78 | 7.34 |
| Interest Coverage Ratio (Post Tax) (X) | 0.75 | 1.03 | 0.94 | 1.37 | 5.21 |
| Enterprise Value (Cr.) | 285.94 | 148.80 | 126.35 | 177.17 | 202.22 |
| EV / Net Operating Revenue (X) | 1.79 | 0.75 | 0.69 | 0.88 | 1.11 |
| EV / EBITDA (X) | 36.15 | 12.53 | 16.05 | 20.51 | 8.46 |
| MarketCap / Net Operating Revenue (X) | 1.53 | 0.46 | 0.41 | 0.69 | 1.01 |
| Retention Ratios (%) | 0.00 | 0.00 | 319.53 | 30.05 | 91.25 |
| Price / BV (X) | 3.50 | 2.00 | 1.65 | 2.97 | 3.95 |
| Price / Net Operating Revenue (X) | 1.53 | 0.46 | 0.41 | 0.69 | 1.01 |
| EarningsYield | -0.01 | 0.00 | 0.00 | 0.01 | 0.07 |
After reviewing the key financial ratios for Everest Organics Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is -2.97. This value is below the healthy minimum of 5. It has decreased from 0.17 (Mar 24) to -2.97, marking a decrease of 3.14.
- For Diluted EPS (Rs.), as of Mar 25, the value is -2.97. This value is below the healthy minimum of 5. It has decreased from 0.17 (Mar 24) to -2.97, marking a decrease of 3.14.
- For Cash EPS (Rs.), as of Mar 25, the value is 4.81. This value is within the healthy range. It has decreased from 7.42 (Mar 24) to 4.81, marking a decrease of 2.61.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 72.03. It has increased from 57.30 (Mar 24) to 72.03, marking an increase of 14.73.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 72.03. It has increased from 57.30 (Mar 24) to 72.03, marking an increase of 14.73.
- For Dividend / Share (Rs.), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 1. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 164.23. It has decreased from 246.55 (Mar 24) to 164.23, marking a decrease of 82.32.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 8.14. This value is within the healthy range. It has decreased from 14.84 (Mar 24) to 8.14, marking a decrease of 6.70.
- For PBIT / Share (Rs.), as of Mar 25, the value is 2.00. This value is within the healthy range. It has decreased from 7.60 (Mar 24) to 2.00, marking a decrease of 5.60.
- For PBT / Share (Rs.), as of Mar 25, the value is -3.34. This value is below the healthy minimum of 0. It has decreased from 0.76 (Mar 24) to -3.34, marking a decrease of 4.10.
- For Net Profit / Share (Rs.), as of Mar 25, the value is -1.33. This value is below the healthy minimum of 2. It has decreased from 0.17 (Mar 24) to -1.33, marking a decrease of 1.50.
- For PBDIT Margin (%), as of Mar 25, the value is 4.95. This value is below the healthy minimum of 10. It has decreased from 6.01 (Mar 24) to 4.95, marking a decrease of 1.06.
- For PBIT Margin (%), as of Mar 25, the value is 1.22. This value is below the healthy minimum of 10. It has decreased from 3.08 (Mar 24) to 1.22, marking a decrease of 1.86.
- For PBT Margin (%), as of Mar 25, the value is -2.03. This value is below the healthy minimum of 10. It has decreased from 0.30 (Mar 24) to -2.03, marking a decrease of 2.33.
- For Net Profit Margin (%), as of Mar 25, the value is -0.80. This value is below the healthy minimum of 5. It has decreased from 0.07 (Mar 24) to -0.80, marking a decrease of 0.87.
- For Return on Networth / Equity (%), as of Mar 25, the value is -1.84. This value is below the healthy minimum of 15. It has decreased from 0.30 (Mar 24) to -1.84, marking a decrease of 2.14.
- For Return on Capital Employeed (%), as of Mar 25, the value is 2.30. This value is below the healthy minimum of 10. It has decreased from 9.12 (Mar 24) to 2.30, marking a decrease of 6.82.
- For Return On Assets (%), as of Mar 25, the value is -0.57. This value is below the healthy minimum of 5. It has decreased from 0.06 (Mar 24) to -0.57, marking a decrease of 0.63.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.13. This value is below the healthy minimum of 0.2. It has decreased from 0.31 (Mar 24) to 0.13, marking a decrease of 0.18.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.68. This value is within the healthy range. It has decreased from 1.26 (Mar 24) to 0.68, marking a decrease of 0.58.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.70. It has decreased from 0.92 (Mar 24) to 0.70, marking a decrease of 0.22.
- For Current Ratio (X), as of Mar 25, the value is 1.06. This value is below the healthy minimum of 1.5. It has increased from 0.93 (Mar 24) to 1.06, marking an increase of 0.13.
- For Quick Ratio (X), as of Mar 25, the value is 0.73. This value is below the healthy minimum of 1. It has increased from 0.66 (Mar 24) to 0.73, marking an increase of 0.07.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 3.58. This value is below the healthy minimum of 4. It has increased from 2.73 (Mar 24) to 3.58, marking an increase of 0.85.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 1.52. This value is below the healthy minimum of 3. It has decreased from 2.17 (Mar 24) to 1.52, marking a decrease of 0.65.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 0.75. This value is below the healthy minimum of 3. It has decreased from 1.03 (Mar 24) to 0.75, marking a decrease of 0.28.
- For Enterprise Value (Cr.), as of Mar 25, the value is 285.94. It has increased from 148.80 (Mar 24) to 285.94, marking an increase of 137.14.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 1.79. This value is within the healthy range. It has increased from 0.75 (Mar 24) to 1.79, marking an increase of 1.04.
- For EV / EBITDA (X), as of Mar 25, the value is 36.15. This value exceeds the healthy maximum of 15. It has increased from 12.53 (Mar 24) to 36.15, marking an increase of 23.62.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 1.53. This value is within the healthy range. It has increased from 0.46 (Mar 24) to 1.53, marking an increase of 1.07.
- For Retention Ratios (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 30. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Price / BV (X), as of Mar 25, the value is 3.50. This value exceeds the healthy maximum of 3. It has increased from 2.00 (Mar 24) to 3.50, marking an increase of 1.50.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 1.53. This value is within the healthy range. It has increased from 0.46 (Mar 24) to 1.53, marking an increase of 1.07.
- For EarningsYield, as of Mar 25, the value is -0.01. This value is below the healthy minimum of 5. It has decreased from 0.00 (Mar 24) to -0.01, marking a decrease of 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Everest Organics Ltd:
- Net Profit Margin: -0.8%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 2.3% (Industry Average ROCE: 16.29%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: -1.84% (Industry Average ROE: 15.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 0.75
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.73
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 73.7 (Industry average Stock P/E: 52.68)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.68
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: -0.8%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | Aroor Village, Sadasivpet Mandal, Sangareddy Dist. Telangana 502291 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Prasad Venkata Satya Sundara Srikakolapu | Chairman & Ind.Director |
| Dr. Sri Kakarlapudi Sirisha | Managing Director |
| Mr. Srikakarlapudi Harikrishna | Whole Time Director |
| Mr. Kirankumar Rampally | Non Exe.Non Ind.Director |
| Mr. Venkata Satyanarayana Murthy Vadali | Independent Director |
FAQ
What is the intrinsic value of Everest Organics Ltd?
Everest Organics Ltd's intrinsic value (as of 30 December 2025) is 100.18 which is 80.04% lower the current market price of 502.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 488 Cr. market cap, FY2025-2026 high/low of 504/211, reserves of ₹63 Cr, and liabilities of 237 Cr.
What is the Market Cap of Everest Organics Ltd?
The Market Cap of Everest Organics Ltd is 488 Cr..
What is the current Stock Price of Everest Organics Ltd as on 30 December 2025?
The current stock price of Everest Organics Ltd as on 30 December 2025 is 502.
What is the High / Low of Everest Organics Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Everest Organics Ltd stocks is 504/211.
What is the Stock P/E of Everest Organics Ltd?
The Stock P/E of Everest Organics Ltd is 73.7.
What is the Book Value of Everest Organics Ltd?
The Book Value of Everest Organics Ltd is 74.7.
What is the Dividend Yield of Everest Organics Ltd?
The Dividend Yield of Everest Organics Ltd is 0.00 %.
What is the ROCE of Everest Organics Ltd?
The ROCE of Everest Organics Ltd is 1.76 %.
What is the ROE of Everest Organics Ltd?
The ROE of Everest Organics Ltd is 2.23 %.
What is the Face Value of Everest Organics Ltd?
The Face Value of Everest Organics Ltd is 10.0.